B7-H3
B7-H3 is an immune-dampening protein on many solid tumours, now used as an ADC address, especially in small-cell lung and prostate cancer. This dossier gathers the 1 product (0 approved), 1 trial, 0 pathways and 1 resistance route in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Function debated: inhibits T-cell activation, promotes tumour cell migration. Expression is more homogeneous than many ADC targets.
- Small-cell lung cancer
- Prostate
- Head and neck
- Paediatric solid tumours
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsHow common it is, by cancer
Full matrix →| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | 80-90% | IHC, any expression | Castration-resistant disease | Wikipedia |
| Small-cell lung cancer | 60-70% | IHC, any expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Products by modality and phase
Browse products →| Modality | Phase 3 |
|---|---|
| ADC 1 |
Trials
Evidence ranking →| Trial | Phase | Status | Setting | Result | Products |
|---|---|---|---|---|---|
| IDeate-Lung02 NCT06203210 | 3 | Recruiting | Relapsed SCLC after one prior line: ifinatamab deruxtecan vs topotecan, amrubicin, or lurbinectedin |
Resistance routes that involve this target
Unaddressed routes →RB1/TP53 loss enables transdifferentiation; AR-indifferent, DLL3-positive, PSMA-negative.
- Platinum-etoposide; DLL3 engagers (tarlatamab) and B7-H3 ADCs in trials
Pathways where it is a node
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics and assays
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →- 01
Does B7-H3 expression predict benefit from ifinatamab deruxtecan in small-cell lung cancer and prostate cancer, or is it another ADC given without a biomarker?
translationalindustryWhy unresolved. B7-H3 is broadly expressed with low normal-tissue expression, and early single-arm data are promising, but no threshold has been validated and payload resistance from prior topotecan or lurbinectedin is plausible.
What would answer it. IDeate-Lung02 with prospective B7-H3 IHC analysis and payload-resistance biomarkers.
Source: IDeate-Lung02 (ClinicalTrials.gov)
Ideas and companies
Key papers and the live literature
Preprints →Query for this target: (TITLE:"B7-H3" OR ABSTRACT:"B7-H3" OR TITLE:"CD276" OR ABSTRACT:"CD276") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about B7-H3, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/b7h3.json. Licence CC BY 4.0.